Advertisement

AMP-Activated Protein Kinase: A Master Switch in Glucose and Lipid Metabolism

  • D. Grahame Hardie
Article
AMP-activated protein kinase glucose uptake Type 2 diabetes obesity metabolic syndrome 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hardie DG, Scott JW, Pan DA, Hudson ER. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 2003;546:113-120.Google Scholar
  2. 2.
    Lang T, Yu L, Tu Q, Jiang J, Chen Z, Xin Y, Liu G, Zhao S. Molecular cloning, genomic organization, and mapping of PRKAG2, a heart abundant gamma(2) subunit of 5′-AMP-activated protein kinase, to human chromosome 7q36 [In Process Citation]. Genomics 2000;70:258-263.Google Scholar
  3. 3.
    Gollob MH, Seger JJ, Gollob TN, Tapscott T, Gonzales O, Bachinski L, Roberts R. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation 2001;104:3030-3033.Google Scholar
  4. 4.
    Salt IP, Celler JW, Hawley SA, Prescott A, Woods A, Carling D, Hardie DG. AMP-activated protein kinase—Greater AMP dependence, and preferential nuclear localization, of complexes containing the α2 isoform. Biochem J 1998;334:177-187.Google Scholar
  5. 5.
    Cheung PCF, Salt IP, Davies SP, Hardie DG, Carling D. Characterization of AMP-activated protein kinase γ subunit isoforms and their role in AMP binding. Biochem J 2000;346:659-669.Google Scholar
  6. 6.
    Crute BE, Seefeld K, Gamble J, Kemp BE, Witters LA. Functional domains of the alpha1 catalytic subunit of the AMP-activated protein kinase. J Biol Chem 1998;273:35347-35354.Google Scholar
  7. 7.
    Scott JW, Hawley SA, Green KA, Anis M, Stewart G, Scullion GA, Norman DG, Hardie DG. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin Invest 2004;113:274-284.Google Scholar
  8. 8.
    Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D, Hardie DG. Characterization of the AMP-activated protein kinase kinase from rat liver, and identification of threonine-172 as the major site at which it phosphorylates and activates AMP-activated protein kinase. J Biol Chem 1996;271:27879-27887.Google Scholar
  9. 9.
    Hawley SA, Selbert MA, Goldstein EG, Edelman AM, Carling D, Hardie DG. 5′-AMP activates the AMP-activated protein kinase cascade, and Ca2+/calmodulin the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. J Biol Chem 1995;270:27186-27191.Google Scholar
  10. 10.
    Davies SP, Helps NR, Cohen PTW, Hardie DG. 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2Cα and native bovine protein phosphatase-2AC. FEBS Lett 1995;377:421-425.Google Scholar
  11. 11.
    Hardie DG, Salt IP, Hawley SA, Davies SP. AMP-activated protein kinase: An ultrasensitive system for monitoring cellular energy charge. Biochem J 1999;338:717-722.Google Scholar
  12. 12.
    Hudson ER, Pan DA, James J, Lucocq JM, Hawley SA, Green KA, Baba O, Terashima T, Hardie DG. A novel domain in AMP-activated protein kinase causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias. Current Biol 2003;13:861-866.Google Scholar
  13. 13.
    Polekhina G, Gupta A, Michell BJ, van Denderen B, Murthy S, Feil SC, Jennings IG, Campbell DJ, Witters LA, Parker MW, Kemp BE, Stapleton D. AMPK β-Subunit targets metabolic stress-sensing to glycogen. Current Biol 2003;13:867-871.Google Scholar
  14. 14.
    Wojtaszewski JFP, Jørgensen SB, Hellsten Y, Hardie DG, Richter EA. Glycogen-dependent effects of AICA riboside on AMP-activated protein kinase and glycogen synthase activities in rat skeletal muscle. Diabetes 2002;51:284-292.Google Scholar
  15. 15.
    Wojtaszewski JF, MacDonald C, Nielsen JN, Hellsten Y, Hardie DG, Kemp BE, Kiens B, Richter EA. Regulation of 5′AMP-activated protein kinase activity and substrate utilization in exercising human skeletal muscle. Am J Physiol 2002;284:E813-E822.Google Scholar
  16. 16.
    Ponticos M, Lu QL, Morgan JE, Hardie DG, Partridge TA, Carling D. Dual regulation of the AMP-activated protein kinase provides a novel mechanism for the control of creatine kinase in skeletal muscle. EMBO J 1998;17:1688-1699.Google Scholar
  17. 17.
    Wilson WA, Hawley SA, Hardie DG. The mechanism of glucose repression/derepression in yeast: SNF1 protein kinase is activated by phosphorylation under derepressing conditions, and this correlates with a high AMP:ATP ratio. Current Biol 1996;6:1426-1434.Google Scholar
  18. 18.
    Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: Metabolic sensors of the eukaryotic cell? Ann Rev Biochem 1998;67:821-855.Google Scholar
  19. 19.
    Sutherland CM, Hawley SA, McCartney RR, Leech A, Stark MJ, Schmidt MC, Hardie DG. Elm1p is one of three upstream kinases for the Saccharomyces cerevisiae SNF1 complex. Curr Biol 2003;13:1299-1305.Google Scholar
  20. 20.
    Hong SP, Leiper FC, Woods A, Carling D, Carlson M. Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc Natl Acad Sci USA 2003;100:8839-8843.Google Scholar
  21. 21.
    Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR, Hardie DG. Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003;2:28.Google Scholar
  22. 22.
    Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M, Carling D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003:DOI: 10.1016/S0960982203007851.Google Scholar
  23. 23.
    Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, Vincent MF, Van den Berghe G, Carling D, Hue L. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Current Biol 2000;10:1247-1255.Google Scholar
  24. 24.
    Salt IP, Johnson G, Ashcroft SJH, Hardie DG. AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic β cells, and may regulate insulin release. Biochem J 1998;335:533-539.Google Scholar
  25. 25.
    Winder WW, Hardie DG. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol 1996;270:E299-E304.Google Scholar
  26. 26.
    Coven DL, Hu X, Cong L, Bergeron R, Shulman GI, Hardie DG, Young LH. Physiologic role of AMP-activated protein kinase (AMPK) in the heart: graded activation during exercise. Am J Physiol 2003;285:E629-E636.Google Scholar
  27. 27.
    Fujii N, Hayashi T, Hirshman MF, Smith JT, Habinowski SA, Kaijser L, Mu J, Ljungqvist O, Birnbaum MJ, Witters LA, Thorell A, Goodyear LJ. Exercise induces isoform-specific increase in 5′AMP-activated protein kinase activity in human skeletal muscle. Biochem Biophys Res Commun 2000;273:1150-1155.Google Scholar
  28. 28.
    Wojtaszewski JF, Nielsen P, Hansen BF, Richter EA, Kiens B. Isoform-specific and exercise intensity-dependent activation of 5′-AMP-activated protein kinase in human skeletal muscle. J Physiol 2000;528:221-226.Google Scholar
  29. 29.
    Carlson CL, Winder WW. Liver AMP-activated protein kinase and acetyl-CoA carboxylase during and after exercise. J Appl Physiol 1999;86:669-674.Google Scholar
  30. 30.
    Ruderman NB, Park H, Kaushik VK, Dean D, Constant S, Prentki M, Saha AK. AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. Acta Physiol Scand 2003;178:435-442.Google Scholar
  31. 31.
    Moule SK, Denton RM. The activation of p38 MAPK by the beta-adrenergic agonist isoproterenol in rat epididymal fat cells. FEBS Lett 1998;439:287-290.Google Scholar
  32. 32.
    Yin W, Mu J, Birnbaum MJ. Role of AMP-activated protein kinase in cyclic AMP-dependent lipolysis In 3T3-L1 adipocytes. J Biol Chem 2003;278:43074-43080.Google Scholar
  33. 33.
    Kishi K, Yuasa T, Minami A, Yamada M, Hagi A, Hayashi H, Kemp BE, Witters LA, Ebina Y. AMP-Activated protein kinase is activated by the stimulations of G(q)-coupled receptors. Biochem Biophys Res Commun 2000;276:16-22.Google Scholar
  34. 34.
    Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-343.Google Scholar
  35. 35.
    Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;6:1288-1295.Google Scholar
  36. 36.
    Winder WW, Hardie DG. The AMP-activated protein kinase, a metabolic master switch: Possible roles in Type 2 diabetes. Am J Physiol 1999;277:E1-E10.Google Scholar
  37. 37.
    Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, Winder WW. 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 1999;48:1667-1671.Google Scholar
  38. 38.
    Zheng D, MacLean PS, Pohnert SC, Knight JB, Olson AL, Winder WW, Dohm GL. Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. J Appl Physiol 2001;91:1073-1083.Google Scholar
  39. 39.
    Lochhead PA, Salt IP, Walker KS, Hardie DG, Sutherland C. 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 2000;49:896-903.Google Scholar
  40. 40.
    Gillespie JG, Hardie DG. Phosphorylation and inactivation of HMG-CoA reductase at the AMP-activated protein kinase site in response to fructose treatment of isolated rat hepatocytes. FEBS Lett 1992;306:59-62.Google Scholar
  41. 41.
    Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-Aminoimidazole-4-carboxamide ribonucleoside: A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 1995;229:558-565.Google Scholar
  42. 42.
    Woods A, Azzout-Marniche D, Foretz M, Stein SC, Lemarchand P, Ferre P, Foufelle F, Carling D. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol 2000;20:6704-6711.Google Scholar
  43. 43.
    Luiken JJ, Coort SL, Willems J, Coumans WA, Bonen A, van der Vusse GJ, Glatz JF. Contraction-induced fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes 2003;52:1627-1634.Google Scholar
  44. 44.
    Merrill GM, Kurth E, Hardie DG, Winder WW. AICAR decreases malonyl-CoA and increases fatty acid oxidation in skeletal muscle of the rat. Am J Physiol 1997;273:E1107-E1112.Google Scholar
  45. 45.
    Winder WW, Holmes BF, Rubink DS, Jensen EB, Chen M, Holloszy JO. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol 2000;88:2219-2226.Google Scholar
  46. 46.
    Zong H, Ren JM, Young LH, Pypaert M, Mu J, Birnbaum MJ, Shulman GI. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci USA 2002;99:15983-15987.Google Scholar
  47. 47.
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.Google Scholar
  48. 48.
    Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350.Google Scholar
  49. 49.
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.Google Scholar
  50. 50.
    Henin N, Vincent MF, Gruber HE, Van den Berghe G. Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase. FASEB J 1995;9:541-546.Google Scholar
  51. 51.
    Gadalla AE, Pearson T, Currie AJ, Dale N, Hawley SA, Randall AD, Hardie DG, Frenguelli BG. Distinct mechanisms underlie the activation of rat brain AMP-activated protein kinase and the inhibition of excitatory synaptic transmission by AICA riboside (Acadesine) in area CA1 of rat hippocampus. J Neurochem 2003;88:1272-1282.Google Scholar
  52. 52.
    Buhl ES, Jessen N, Pold R, Ledet T, Flyvbjerg A, Pedersen SB, Pedersen O, Schmitz O, Lund S. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 2002;51:2199-2206.Google Scholar
  53. 53.
    Bergeron R, Previs SF, Cline GW, Perret P, Russell RR, 3rd Young, LH Shulman, GI. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 2001;50:1076-1082.Google Scholar
  54. 54.
    Song XM, Fiedler M, Galuska D, Ryder JW, Fernström M, Chibalin AV, Wallberg-Henriksson H, Zierath JR. 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia 2002;45:56-65.Google Scholar
  55. 55.
    Iglesias MA, Ye JM, Frangioudakis G, Saha AK, Tomas E, Ruderman NB, Cooney GJ, Kraegen EW. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 2002;51:2886-2894.Google Scholar
  56. 56.
    Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174.Google Scholar
  57. 57.
    Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The anti-diabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002;51:2420-2425.Google Scholar
  58. 58.
    Fryer LG, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct pathways. J Biol Chem 2002;277:25226-25232.Google Scholar
  59. 59.
    Gollob MH, Green MS, Tang ASL, Gollob T, Karibe A, Hassan AS, Ahmad F, Lozado R, Shah G, Fananapazir L, Bachinski LL, Roberts R. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. New Eng J Med 2001;344:1823-1831.Google Scholar
  60. 60.
    Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, Kerr B, Salmon A, Ostman-Smith I, Watkins H. Mutations in the gamma-2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: Evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001;10:1215-1220.Google Scholar
  61. 61.
    Arad M, D.W. B, Perez-Atayde AR, McKenna WJ, Sparks EA, Kanter RJ, McGarry K, Seidman JG, Seidman CE. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 2002;109:357-362.Google Scholar
  62. 62.
    Daniel TD, Carling D. Functional analysis of mutations in the γ2 subunit of AMP-activated protein kinase associated with cardiac hypertrophy and Wolff-Parkinson-White syndrome. J Biol Chem 2002;277:51017-51024.Google Scholar
  63. 63.
    Milan D, Jeon JT, Looft C, Amarger V, Robic A, Thelander M, Rogel-Gaillard C, Paul S, Iannuccelli N, Rask L, Ronne H, Lundstrom K, Reinsch N, Gellin J, Kalm E, Roy PL, Chardon P, Andersson L. A mutation in PRKAG3 associated with excess glycogen content in pig skeletal muscle. Science 2000;288:1248-1251.Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • D. Grahame Hardie
    • 1
  1. 1.Division of Molecular Physiology, Wellcome Trust BiocentreUniversity of DundeeScotlandUK

Personalised recommendations